SCHEMBL5007401

SCHEMBL5007401

CC(C)(CC(=O)O)c1ccccc1OP(=O)(O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 3/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
PDE3A Q14432 1/20 0.49
HSD17B10 Q99714 1/20 0.49
INPPL1 O15357 3/20 0.42
INPP5A Q14642 3/20 0.42
INPP5B P32019 2/20 0.42
SRC P12931 2/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
AKT1 P31749 1/20 0.37
GAA P10253 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
ATM Q13315 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18121460 0.87 ALDH1A1 (0.44) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL18114061 0.85 ALDH1A1 (0.43) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL18607332 0.85 KDM4E (0.43) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL19629845 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL20696702 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL18114020 0.83 GLA (0.38) CYP2C19HIF1ANPSR1RXRARXRB
SCHEMBL27859933 0.83 INPPL1 (0.46) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL1354464 0.81 INPPL1 (0.44) ALDH1A1KDM4EUSP2HPGDPDE3A
SCHEMBL30040484 0.81 POLB (0.50) ALDH1A1CYP2C19HIF1ANPSR1GAA
SCHEMBL6892090 0.81 POLB (0.50) ALDH1A1CYP2C19HIF1ANPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017036968-A1 ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-03-09 WO disclosed
WO-2017037039-A1 ANTIBACTERIAL HETEROCYCLIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-03-09 WO disclosed
US-20080287396-A1 Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections TARGANTA THERAPEUTICA INC. (CA) 2008-11-20 US disclosed
EP-1881974-A2 PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS Targanta Therapeutics Inc. (CA) 2008-01-30 EP disclosed
WO-2007017762-A2 PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS TARGANTA THERAPEUTICS INC. (CA) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287396-A1 Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections BPGM, PSPH, PGLS ALDH1A1 4175/4885KDM4E 3645/4885USP2 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.